Search research articles
Contact Us
Filters
Showing results (131-140 of 168) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer
G D'Andrea, D Fennelly, L Norton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2002
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
M D Green, H Koelbl, J Baselga, et al.
Seminars in Oncology
|
September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga, D Rischin, M Ranson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 11, 2011
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
C Serrano, J Cortés, L De Mattos-Arruda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
C Serrano, J Cortés, L De Mattos-Arruda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2004
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
J Tabernero, M A Climent, A Lluch, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 168) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer
G D'Andrea, D Fennelly, L Norton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2002
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
M D Green, H Koelbl, J Baselga, et al.
Seminars in Oncology
|
September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga, D Rischin, M Ranson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 11, 2011
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
C Serrano, J Cortés, L De Mattos-Arruda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors
C Serrano, J Cortés, L De Mattos-Arruda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2004
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
J Tabernero, M A Climent, A Lluch, et al.
Page
of 17